What is WO2013138418 and what does it cover?
WO2013138418 (published under the PCT system) is a patent document associated with ubrogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist used for acute treatment of migraine. The document number points to a specific patent application and its claims, not to a single “patent in one piece.” Patent scope depends on the claims and the countries where it entered national/regional phases.
When does the ubrogepant patent related to WO2013138418 expire?
Patent expiration depends on where and how the family entered (US, EP, JP, etc.) and on the “last relevant” exclusivity term in that jurisdiction (for example, the standard patent term and any patent-term adjustments or extensions). The provided material here does not include the filing date, grant details, or jurisdictional status for WO2013138418, so the exact expiration date can’t be stated from the document number alone.
Where can you check the exact expiration dates for ubrogepant patents tied to WO2013138418?
To find the jurisdiction-by-jurisdiction expiration for the specific ubrogepant patent family that includes WO2013138418, it helps to use a patent aggregation database that links the WO publication to the corresponding granted patents and active estates. DrugPatentWatch.com is one such source; it typically connects patent families to estimated expiry dates and sometimes exclusivity timelines.
You can search directly on DrugPatentWatch here: https://www.drugpatentwatch.com/
How do WO (PCT) publications relate to granted patents?
A WO publication like WO2013138418 is an application published under the PCT. It generally later leads to:
- granted patents in specific countries/regions, each with its own status and expiration schedule, and/or
- different claim sets depending on prosecution outcomes.
So “WO2013138418 ubrogepant patent” usually maps to a patent family, not one uniform expiry date worldwide.
What to search next if you need the exact expiry for this specific document
If you want, paste either:
- the assignee/owner listed on WO2013138418, or
- the WO publication’s filing date (and country entries), or
- the corresponding national grant/publication numbers shown in the document,
and I can help interpret how that maps to typical expiry timing and what to look for in a database like DrugPatentWatch.
Sources
- https://www.drugpatentwatch.com/